Cargando…
Myocarditis following mRNA Covid-19 vaccination: A pooled analysis
BACKGROUND: Post-marketing surveillance studies have raised concerns of increased myocarditis rates following coronavirus disease-19 (Covid-19) mRNA vaccines. The present study aims to accumulate the published mRNA Covid-19 vaccine-associated myocarditis cases, describe their clinical characteristic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818354/ https://www.ncbi.nlm.nih.gov/pubmed/35153093 http://dx.doi.org/10.1016/j.vaccine.2022.02.017 |
_version_ | 1784645810635407360 |
---|---|
author | Bellos, Ioannis Karageorgiou, Vasilios Viskin, Dana |
author_facet | Bellos, Ioannis Karageorgiou, Vasilios Viskin, Dana |
author_sort | Bellos, Ioannis |
collection | PubMed |
description | BACKGROUND: Post-marketing surveillance studies have raised concerns of increased myocarditis rates following coronavirus disease-19 (Covid-19) mRNA vaccines. The present study aims to accumulate the published mRNA Covid-19 vaccine-associated myocarditis cases, describe their clinical characteristics and determine the factors predisposing to critical illness. METHODS: Medline, Scopus, Web of Science, CENTRAL and Google Scholar were systematically searched from inception. Studies reporting adult myocarditis cases following BNT162b2 or mRNA-1273 vaccination were included. Individual participant data coming from case reports/series were pooled. Proportional random-effects meta-analysis was conducted by combining the pooled cohort and observational studies with aggregated data. RESULTS: Overall, 39 studies were included with a total of 129 patients. Most cases occurred in young males after the second vaccine dose. Myocarditis after the first dose was significantly associated with prior Covid-19 (p-value: 0.025). The most common electrocardiographic finding was ST-segment elevation, while late gadolinium enhancement was invariably observed in cardiac magnetic reasoning. Logistic regression analysis demonstrated that signs of heart failure were predictive of subsequent critical illness (Odds ratio: 19.22, 95% confidence intervals-CI: 5.57–275.84). Proportion meta-analysis indicated that complete resolution of symptoms is achieved in 80.5% of patients (95% CI: 59.3–92.1), while the proportion of participants necessitating intensive care unit admission is 7.0% (95% CI: 3.8–12.9). CONCLUSIONS: Myocarditis following mRNA Covid-19 vaccination is typically mild, following an uncomplicated clinical course with rapid improvement of symptoms. Future research is needed to define its exact incidence, clarify its pathophysiology and determine the optimal management plan depending on its severity. Protocol registration: dx.https://doi.org/10.17504/protocols.io.bxwtppen. |
format | Online Article Text |
id | pubmed-8818354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88183542022-02-07 Myocarditis following mRNA Covid-19 vaccination: A pooled analysis Bellos, Ioannis Karageorgiou, Vasilios Viskin, Dana Vaccine Article BACKGROUND: Post-marketing surveillance studies have raised concerns of increased myocarditis rates following coronavirus disease-19 (Covid-19) mRNA vaccines. The present study aims to accumulate the published mRNA Covid-19 vaccine-associated myocarditis cases, describe their clinical characteristics and determine the factors predisposing to critical illness. METHODS: Medline, Scopus, Web of Science, CENTRAL and Google Scholar were systematically searched from inception. Studies reporting adult myocarditis cases following BNT162b2 or mRNA-1273 vaccination were included. Individual participant data coming from case reports/series were pooled. Proportional random-effects meta-analysis was conducted by combining the pooled cohort and observational studies with aggregated data. RESULTS: Overall, 39 studies were included with a total of 129 patients. Most cases occurred in young males after the second vaccine dose. Myocarditis after the first dose was significantly associated with prior Covid-19 (p-value: 0.025). The most common electrocardiographic finding was ST-segment elevation, while late gadolinium enhancement was invariably observed in cardiac magnetic reasoning. Logistic regression analysis demonstrated that signs of heart failure were predictive of subsequent critical illness (Odds ratio: 19.22, 95% confidence intervals-CI: 5.57–275.84). Proportion meta-analysis indicated that complete resolution of symptoms is achieved in 80.5% of patients (95% CI: 59.3–92.1), while the proportion of participants necessitating intensive care unit admission is 7.0% (95% CI: 3.8–12.9). CONCLUSIONS: Myocarditis following mRNA Covid-19 vaccination is typically mild, following an uncomplicated clinical course with rapid improvement of symptoms. Future research is needed to define its exact incidence, clarify its pathophysiology and determine the optimal management plan depending on its severity. Protocol registration: dx.https://doi.org/10.17504/protocols.io.bxwtppen. Elsevier Ltd. 2022-03-15 2022-02-07 /pmc/articles/PMC8818354/ /pubmed/35153093 http://dx.doi.org/10.1016/j.vaccine.2022.02.017 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Bellos, Ioannis Karageorgiou, Vasilios Viskin, Dana Myocarditis following mRNA Covid-19 vaccination: A pooled analysis |
title | Myocarditis following mRNA Covid-19 vaccination: A pooled analysis |
title_full | Myocarditis following mRNA Covid-19 vaccination: A pooled analysis |
title_fullStr | Myocarditis following mRNA Covid-19 vaccination: A pooled analysis |
title_full_unstemmed | Myocarditis following mRNA Covid-19 vaccination: A pooled analysis |
title_short | Myocarditis following mRNA Covid-19 vaccination: A pooled analysis |
title_sort | myocarditis following mrna covid-19 vaccination: a pooled analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818354/ https://www.ncbi.nlm.nih.gov/pubmed/35153093 http://dx.doi.org/10.1016/j.vaccine.2022.02.017 |
work_keys_str_mv | AT bellosioannis myocarditisfollowingmrnacovid19vaccinationapooledanalysis AT karageorgiouvasilios myocarditisfollowingmrnacovid19vaccinationapooledanalysis AT viskindana myocarditisfollowingmrnacovid19vaccinationapooledanalysis |